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ABSTRACT
Introduction: Prostate cancer is the most prevalent neoplastic disease in men. After diagnosis, different treat-
ment regimens are proposed based on the stage of the cancer. These treatments affect physical and muscle 
function, quality of life, and prognosis differently. Objectives: To assess fatigue, muscle strength, muscle thickness, 
and muscle quality in prostate cancer survivors undergoing androgen deprivation therapy (ADT). Methods: Ten 
ADT patients, eight non-ADT patients and 18 healthy control subjects were enrolled in this study. Perceived fatigue 
was assessed through the 20-item Multidimensional Fatigue Inventory. Muscle thickness and quality (e.g., echo 
intensity) were assessed through B-mode ultrasound. Muscle strength and work capacity were assessed using an 
isokinetic dynamometer. The groups were compared with one-way ANOVA and Bonferroni adjustment. Results: 
Muscle thickness, peak torque, and work capacity were lower in ADT than in the control group (CON) (p = 0.021; 
p = 0.005; p <0.001, respectively). ADT showed greater echo intensity than CON (p = 0.005) and N-ADT (p = 0.046). 
There were no differences between N-ADT and CON in terms of muscle thickness, peak torque, work capacity, and 
echo intensity (p >0.05). General fatigue was greater in both ADT (p = 0.030) and N-ADT (p = 0.047) compared 
to CON. Physical fatigue was greater in ADT than CON (p = 0.006). Conclusion: ADT patients showed lower levels 
of muscle function and greater levels of perceived fatigue than healthy control subjects. It appears that muscle 
function remains lower in ADT patients, even several years after treatment initiation, although this does not apply 
to non-ADT patients. Level of evidence II; Diagnostic Studies - Investigating a Diagnostic Test.
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RESUMO
Introdução: O câncer de próstata é a doença neoplásica mais frequente nos homens. Após seu diagnóstico, diferentes 
métodos de tratamento são propostos baseados no estágio do câncer. Esses tratamentos afetam diferentemente a função 
física e muscular, qualidade de vida e o prognóstico. Objetivos: Avaliar a fadiga, força muscular, espessura muscular e a 
qualidade muscular dos sobreviventes ao câncer de próstata que foram submetidos a terapia de privação androgênica 
(ADT). Métodos: Dez pacientes ADT, oito não ADT (N-ADT) e 18 indivíduos saudáveis no grupo controle (CON) foram ins-
critos neste estudo. A fadiga percebida foi avaliada através do Multidimensional Fatigue Inventory composto por 20 itens. 
A espessura e qualidade musculares (eco-intensidade) foram avaliadas através de um aparelho de ultrassom B-mode. A 
força muscular e a capacidade de trabalho foram avaliadas utilizando um dinamômetro isocinético. Os grupos foram 
comparados através de ANOVA de um fator e ajuste de Bonferroni. Resultados: O grupo ADT apresentou menor espessura 
muscular, pico de torque e capacidade de trabalho do que o grupo controle (p = 0,021; p = 0,005; p < 0,001, respectiva-
mente). O grupo ADT demonstrou maior eco-intensidade que o grupo controle (p = 0,005) e N-ADT (p = 0,046). Não foram 
encontradas diferenças entre o grupo N-ADT e CON quanto à espessura muscular, pico de torque, capacidade de trabalho 
e eco-intensidade (p > 0,05). A fadiga geral foi maior tanto no grupo ADT (p = 0,030) quanto no grupo N-ADT (p = 0,047) 
quando comparada ao grupo CON. A fadiga física foi maior no grupo ADT do que no grupo CON (p = 0,006). Conclusão: 
Os pacientes submetidos à terapia de privação androgênica demonstraram menores níveis de função muscular e maiores 
níveis de fadiga percebida do que os indivíduos saudáveis do grupo controle. Parece que a função muscular permanece 
menor em pacientes submetidos à ADT vários anos após o início do tratamento, o que não ocorre com os pacientes N-ADT. 
Nível de evidência II; Estudos diagnósticos - Investigação de um exame para diagnóstico.
Descritores: Neoplasias da próstata; Fadiga; Força muscular; Aptidão física.
RESUMEN
Introducción: El cáncer de próstata es la enfermedad neoplásica más frecuente en los hombres. Después de su 
diagnóstico, diferentes métodos de tratamiento son propuestos basados en la etapa del cáncer. Estos tratamientos 
afectan de forma diferente la función física y muscular, la calidad de vida y el pronóstico. Objetivos: Evaluar la fati-
ga, fuerza muscular,  espesor muscular, y la calidad muscular de sobrevivientes al cáncer de próstata que fueron 
sometidos a la terapia de privación de andrógenos (ADT). Métodos: Diez pacientes ADT, ocho no ADT (N-ADT) y 18 
individuos sanos en el grupo control (CON) fueron inscriptos en este estudio. La fatiga percibida fue evaluada a tra-
vés del Multidimensional Fatigue Inventory compuesto por 20 ítems. El espesor y calidad muscular (eco intensidad) 
fueron evaluadas a través de un aparato de ultrasonido B-mode. La fuerza muscular y la capacidad de trabajo fueron 
evaluadas en un dinamómetro isocinético. Los grupos fueron comparados a través de ANOVA de un factor y ajuste de 
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Bonferroni. Resultados: El grupo ADT demostró menor espesor muscular, pico de torque y capacidad de trabajo que 
el grupo control (p = 0,021; p = 0,005; p <0,001, respectivamente). El grupo ADT demostró mayor eco intensidad que 
el grupo control (p = 0,005) y N-ADT (p = 0,046). No se encontraron diferencias entre el grupo N-ADT y el grupo CON, 
con respecto al espesor muscular, pico de torque, capacidad de trabajo y eco intensidad (p > 0,05). La fatiga general 
fue mayor tanto en el grupo ADT (p = 0,030) como en el grupo N-ADT (p = 0,047), cuando comparada al grupo CON. 
La fatiga física fue mayor en el grupo ADT que en el grupo CON (p = 0,006). Conclusión: Los pacientes sometidos a la 
terapia de privación de andrógenos demostraron menores niveles de función muscular y mayores niveles de fatiga 
percibida que los individuos saludables del grupo control. Parece que la función muscular permanece menor en 
pacientes sometidos a ADT varios años después del inicio del tratamiento, lo que no ocurre con los pacientes N-ADT. 
Nivel de evidencia II; Estudios de diagnóstico - Investigación de un examen de diagnóstico.
Descriptores: Neoplasias de la próstata; Fatiga; Fuerza muscular; Aptitud Física.
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INTRODUCTION
Prostate cancer (PC) is classified as a global burden issue by the World Health 
Organization, since it is the most prevalent neoplastic disease in men.1 Only in 
United States, PC is responsible for 20% of new cancer diagnoses in men.2 The 
rises in PC’s incidence is related to population ageing and to the exposure to 
risk factors, such as unhealthy lifestyles.3 Although aging could be considered 
the main risk factor, lifestyle and ethnicity also affects PC’s incidence.3,4
After diagnosis, several interventions could be applied to treat PC. 
The most prevalent treatment regimens in early stages of PC are radio-
therapy, radical prostatectomy, or the combination between them.5,6 
However, in progressive stages of PC, androgen deprivation therapy 
(ADT) is widely used in order to reduce testosterone levels and attenuate 
PC’s progression, leading to fall in 90% of prostatic specific antigen.
Although all regimens of treatment aim to defeat PC, they could affect 
distinctly quality of life and physical function.7 Therefore, both cancer and 
therapy could induce late side effects directly related to severity of such 
therapy and disease.5,8 PC survivors submitted to radiotherapy and radical 
prostatectomy usually report urinary dysfunction, sexual impotence, and 
intestinal disorders.9 Otherwise, PC survivors submitted to ADT could report 
cardiovascular impairments, depression, anemia, osteoporosis, and loss of 
muscle tissue. Recent studies showed the effect of ADT after only three 
months of treatment, leading to lower strength and functionality, and 
greater fatigue than non-ADT PC survivors.10 Furthermore, long-term ADT 
could deteriorate physical function and increase the risk of cardiovascular 
disease, insulin resistance and metabolic syndrome.11,12
Considering that both incidence and survivorship are rising due to 
aging population, unhealthy habits and screening improvement, the 
growing population of survivors requires specialized follow-up and 
care.13 Only two studies have examined physical functions in PC survivors 
submitted do ADT and non-ADT.10 However, both studies only assessed 
survivors up to 12 months after the treatment beginning. Also, both 
studies used non-gold standard field tests to assess muscle function. 
Therefore, it is mandatory to understand the effects of different regimens 
of treatment for prostate cancer in order to provide a better long-term 
care and to clarify the magnitude of late side effects, even several years 
after the beginning of therapy. So, the purpose of the present study was 
to assess muscle strength, muscle thickness and muscle quality in prostate 
cancer survivors submitted to androgen deprivation therapy. Therefore, 
prostate cancer survivors submitted to ADT were compared to prostate 
cancer survivors submitted to non-ADT and to control healthy subjects.
METHODS
Subjects
All participants were volunteers recruited from community, by word 
of mouth and advertisements on Internet. Prostate cancer survivors were 
also recruited from public and private local hospitals. The participants 
were informed of the purpose, procedures and risks of the study prior 
to signing an informed consent. The procedures were approved by the 
University Institutional Review Board. Ten PC survivors were included in 
ADT group, eight PC survivors that undergone non-ADT therapies, such as 
radical prostatectomy and/or radiotherapy, were included in N-ADT group, 
and eighteen control healthy subjects matched by age were included in 
control group (CON). Patients were included in ADT and N-ADT groups 
if they were diagnosed with non-metastatic prostate cancer through a 
prostate biopsy. Additionally, participants included in ADT group must have 
been performing androgen deprivation therapy for at least 12 months. 
Healthy control subjects included in CON were selected based on similar 
age and absence of cancer diagnosis. Participants were excluded of this 
study if they were diagnosed with hypertension, cardiovascular, metabolic 
and/or neuroendocrine disease, and/or had any orthopedic limitation. All 
procedures performed in this study were in accordance with the ethical 
standards of the institutional and/or national research ethical committee 
(CAAE: 94882218.8.0000.0023) and with the 1964 Helsinki declaration and 
its later amendments or comparable ethical standards. Informed consent 
was obtained from all individual participants included in the study.
Experimental procedures
After signing the informed consent form, the participants reported 
to the Strength Training Research Laboratory for testing. All groups 
performed the following tests and evaluations in the same sequence: 
1) self-perceived fatigue, 2) anthropometrics measurements, 3) muscle 
thickness and echo intensity, and 4) strength and work capacity. All 
evaluations were performed at the same period of the day (afternoon), 
by the same researcher, in a controlled temperature room, from January 
to April 2018. All participants were asked to follow pre-assessment 
guidelines before reporting to the laboratory including: avoid physical 
exertion for at least 48 hours prior to the evaluations.
Self-perceived fatigue
Self-perceived fatigue was measured through MFI-20. This question-
naire was designed to asses’ different levels of fatigue between different 
subjects, groups and/or different conditions, as well as various popula-
tions. Several dimensions comprise the questionnaire, which measure 
fatigue experienced in previous days. In this study, general fatigue and 
physical fatigue were used as markers of self-perceived fatigue.
Muscle thickness and quality
Muscle thickness (MT) was measured using B-mode ultrasound 
(Philips, VMI, Brazil). A 7.5-MHz scanning probe was placed on the skin 
perpendicular to the tissue interface. The scanning probe was coated 
with a water-soluble transmission gel to provide acoustic contact without 
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depressing the dermal surface. No additional pressure was applied to 
standardize the compression on the dermal surface. Before measure-
ment, all volunteers rested for 10 minutes in order to guarantee the 
rest condition and to avoid the influence of any body fluids disordered 
by walking. The MT images were determined in lower-body muscles 
including the rectus femoris and vastus intermedius. The measurement 
was taken at 60% of the distance from the greater trochanter to the 
lateral epicondyle and 3 cm lateral to the midline of the anterior thigh. 
Once the examiner found a satisfactory image, it was frozen, stored and 
analyzed using the software Image-J (National Institute of Health, USA, 
version 1.49). The distance between subcutaneous adipose tissue-rectus 
femoris interface and vastus intermedius-bone interface was designated 
as MT. All measurements and analyses were performed three times by 
the same researcher and the mean value was used for analysis.
Muscle quality was assessed by echo intensity (EI). The EI was determi-
ned by gray-scale analysis using the standard histogram function Image-J. 
In order to assess EI in the rectus femoris, a region of interest was selected 
in muscle without any bone or surrounding fascia, with a depth limit of 5 
cm. When this setting was insufficient to display the entire muscle, only 
the superficial part was used for analysis. A reliable measurement of EI is 
extracted from a minimum of 15% of muscle area.14 The EI was expres-
sed in values between 0 (black) and 256 (white). The increase in EI value 
represents a decrease in muscle quality. In our laboratory, the ultrasound 
intra-rater reliability was 0.94 and the coefficient of variation was 2.4%.
Peak torque and work capacity
Isokinetic muscle strength (peak torque (PT)) and work capacity (WC) 
was measured using an isokinetic Biodex System 3 (Biodex Medical, Inc., 
Shirley NY, USA) dynamometer. Subjects were positioned on the dynamo-
meter seat with safety belts fastened to the trunk, pelvis and thigh to avoid 
extraneous body movements. The lateral epicondyle of the femur was used 
to align the knee rotation axis and the dynamometer rotation axis, allowing 
free knee extension and flexion from 85º flexion to full extension. Gravity 
correction was obtained by measuring the torque exerted by the lever arm 
and the participant’s leg at 30º flexion as well as in a relaxed position. The 
values of the isokinetic variables were automatically adjusted for gravity 
with the software Biodex Advantage (Biodex Medical, Inc., Shirley NY, USA). 
The calibration of dynamometer was carried out according to the specifi-
cations provided by the manufacture. For the test, participants were asked 
to cross their arms across the chest. The same researcher carried out the 
test procedures for all participants and provided verbal encouragement.
As part of warm-up and familiarization with isokinetic knee extension 
and warm-up, subjects performed one set of 10 submaximal knee iso-
kinetic extension at 120º.s-.1 Two minutes after familiarization/warm-up 
session, volunteers performed two sets of four maximal isokinetic knee 
extension at 60º/s.15 The greatest torque achieved in both sets was 
considered (PT). WC was also measured on the right knee extensors. 
Three minutes after strength protocol, volunteers performed 30 maximal 
isokinetic knee extensions at 120º/s for WC evaluation. Work capacity 
was calculated as the amount of torque produced throughout the entire 
range of motion of all repetitions. Test-retest reliability coefficient (ICC) 
value for knee extensor peak torque was 0.91 in our laboratory.
Statistical Analysis
Data are presented as mean ± standard deviation. Normal distribution 
parameters were checked with Shapiro-Wilk test. To compare anthropo-
metric characteristics, muscle strength, muscle quality and perceived 
fatigue between all groups, one-way analyses of variance were used. 
The Bonferroni adjustment was applied as post-hoc analysis. The Statistical 
Package for Social Sciences (SPSS), version 21.0 (IBM, USA) was used for 
all analyses. The alpha level was set at 5% (p ≤ 0.05). 
RESULTS
Ten PC survivors composed ADT group, eight PC survivors composed 
N-ADT group, and 18 apparently healthy men composed CON group. 
ADT and N-ADT clinical characteristics are reported in Table 1.
Descriptive and comparative data analysis of ADT, N-ADT and CON 
are reported in Table 2. No significant differences in any physical cha-
racteristics between ADT, N-ADT and CON were observed (p > 0.05).
Muscle function, muscle quality and fatigue variables are presen-
ted in Figure 1. The one-way analyses of variance showed a significant 
effect between groups on muscle thickness (F = 4.158; p = 0.025), peak 
torque (F = 5.983; p = 0.006), work capacity (F = 9.529; p = 0.001), echo 
Table 1. Clinical Characteristics of ADT and N-ADT, expressed as mean ± SD.
Clinical Characteristics ADT (n = 10) N-ADT (n = 8)
Sessions of CT 3.90 ± 1.29 0
Sessions of RT 2.50 ± 4.08 4.63 ± 4.69
Years from treatment begins 5.10 ± 3.12 5.60 ± 3.53
Age at diagnosis 69.80 ± 5.57 64.75 ± 4.58
CT: chemotherapy; RT: radiotherapy; ADT: androgen deprivation therapy group; N-ADT: non-androgen depriva-
tion therapy.
Table 2. Descriptive and comparative data of all groups, expressed in mean ± stan-
dard deviation.
Variable ADT (n = 10) N-ADT (n = 08) CON (n = 18)
Age (years) 74.40 ± 5.76 69.75 ± 5.92 72.17 ± 6.54
Weight (kg) 77.44 ± 14.75 82.25 ± 9.20 77.94 ± 9.47
Height (m) 1.63 ± 0.07 1.70 ± 0.07 1.69 ± 0.07
BMI (kg.m-2) 28.87 ± 4.42 28.68 ± 3.41 27.40 ± 2.91
ADT: androgen deprivation therapy group; N-ADT: non-androgen deprivation therapy; CON: control group; BMI: 
body mass index.
Figura 1. Variables of muscle function and fatigue in ADT, N-ADT and CON. (A) 
muscle thickness, (B) peak torque, (C) work capacity, (D) echo intensity, (E) general 
fatigue, (F) physical fatigue. 
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intensity (F = 6.192; p = 0.005), general fatigue (F = 5.244; p = 0.011), 
and physical fatigue (F = 5.880; p = 0.007). ADT group showed lower 
muscle thickness, peak torque, and work capacity than CON (p = 0.021; 
p = 0.005; p < 0.001, respectively). ADT showed greater echo intensity 
than CON (p = 0.005) and N-ADT (p = 0.046). There were no differences 
between N-ADT and CON on muscle thickness, peak torque, work capa-
city, and echo intensity (p > 0.05). General fatigue was greater in both ADT 
(p = 0.030) and N-ADT (p = 0.047) compared to CON. Physical fatigue was 
greater in ADT than CON (p = 0.006). There was no difference between 
N-ADT and CON on physical fatigue (p = 0.797).
DISCUSSION
The purpose of the present study was to assess muscle strength, 
thickness and quality in prostate cancer survivors submitted to androgen 
deprivation therapy, and to compare ADT patients to non-ADT patients 
and control healthy subjects. Therefore, the main results suggest that 
ADT patients showed lower muscle thickness and function, and greater 
perceived fatigue than control healthy subjects. Also, non-ADT prostate 
cancer survivors showed greater general fatigue than control healthy 
subjects, despite no differences in muscle function between them.
Testosterone inhibition in PC patients could affect skeletal muscle 
tissue due to upregulation of myostatin, imbalance between muscle 
protein breakdown and synthesis, and attenuation of hypertrophic 
pathways Akt/mTOR/P70S6K.16,17 Moreover, mitochondrial dysfunction 
induced by both disease and treatment could affect skeletal muscle 
tissue due to reductions in AMPK and PGC1-α expression, and reactive 
oxygen species overproduction.18 In this study PC patients submitted 
to ADT showed lower muscle thickness than CON, while no difference 
was observed between non-ADT patients and CON. Likewise, Chang 
et al. (2014)19 showed a substantial reduction in muscle tissue of PC 
survivors after 20 week of testosterone deprivation. Indeed, such re-
duction could last for several years after the treatment beginning, as 
suggested in this study.
Regarding muscle strength, ADT patients showed lower peak torque 
than CON, while no difference was observed between non-ADT patients 
and CON. Considering that muscle strength is directly related to muscle 
tissue amount,16 the lower peak torque in ADT compared to CON could 
be explained by the lower muscle thickness. Moreover, physiological 
dysfunctions induced by both treatment and disease, such as Warburg 
effect, acidosis and oxidative stress, could also reduce muscle strength.20,21 
Therefore, several studies have already showed lower muscle strength 
in ADT patients compared to CON.22 However, this study showed that 
muscle strength remains lower in ADT patients compared to healthy 
subjects even several years after the treatment beginning.
Furthermore, physiological impairments induced by both cancer 
and treatment could also affect the ability of the muscle tissue to 
perform multiple repetitions or prolonged tasks, exposing fatigue 
objectively. Falls in work capacity occurs due to reduced glycogen 
content and impaired glucose transport in response to insulin.23 Can-
cer survivors may show an increased systemic acidity due to Warburg 
effect and overproduction of hydrogen ions,24 which affect glycogen’s 
production and content. Otherwise, insulin sensibility could also 
affect glucose transportation and work capacity. The inflammatory 
imbalance in cancer survivors could play a role in insulin resistance, 
since an increased pro-inflammatory cytokines release reduces insu-
lin sensibility.25 Furthermore, insulin resistance is a well-established 
adverse effect of ADT, induced by gonadotropin-releasing hormone 
agonists.26 Therefore, it is not unexpected that PC survivors submitted 
to ADT show lower work capacity, even several years after the 
treatment beginning.
Echo intensity is frequently used as an indicator of muscle quality 
because it represents the accumulation of intramuscular adipose and 
connective tissue. A decreased muscle quality has already been reported 
in diseases such as chronic obstructive pulmonary disease and diabe-
tes.27 However, in cancer survivors, de Lima FD, et al. (2018)15 showed 
no differences between physically active Hodgkin’s lymphoma survivors 
and healthy subjects matched by age and gender. Apparently, active 
Hodgkin’s lymphoma survivors recover their muscle characteristics 
and functions after treatment, and time since treatment completion 
seems to affect positively muscle function in Hodgkin’s disease.15 In 
our study, PC survivors submitted to ADT showed worse muscle quality 
than both non-ADT patients and control healthy subjects, even several 
years after the treatment beginning. Such phenomenon could be 
justified by imbalance between protein breakdown and synthesis,16,17 
and metabolic dysfunctions.26
Another interesting finding of this study is the greater general 
fatigue reported by both ADT and non-ADT PC survivors, while only 
ADT patients showed a greater physical fatigue compared to control 
healthy subjects. An increased general fatigue is widely reported in 
cancer survivors and has been already described in several cancer 
types.28,29 According O’Higgins, et al. (2018)30 a cascade of biochemical, 
physiological, and psychological dysregulation of important biological 
systems contribute to cancer-related fatigue. Actually, a greater general 
fatigue is reported by cancer survivors even when muscle functions 
are preserved,15 suggesting that disease may play a role in general 
fatigue more than treatment.
Otherwise, only ADT patients showed greater physical fatigue 
than control healthy subjects. The physical fatigue assessed in Mul-
tidimensional Fatigue Inventory 20-item is related to the percep-
tion of physical exhaustion and could be indeed related to muscle 
characteristics and functions. Consequently, the increased physical 
fatigue in ADT patients is explained by the worse muscle strength, 
muscle thickness, muscle quality and work capacity compared to 
control healthy subjects.
This cross-sectional study was not without limitations. An important 
limitation was the small size of the sample. Evidently, these statements 
above are simply speculations at this time and more research is needed 
to confirm or refute these possibilities. However, this study should be 
seen as a hypothesis-generating study, providing initial information 
about fatigue mechanisms and muscle function in prostate cancer 
survivors even several years after the treatment beginning. Also, to 
the best of our knowledge, this is the first study that applied both 
subjective and objective markers of fatigue together. For future re-
search, it is recommended that a larger sample size and other cancer 
types be included.
CONCLUSION
In summary, a lower level of muscle function and a higher level of 
self-perceived fatigue were observed in prostate cancer survivors sub-
mitted to androgen deprivation therapy compared to control healthy 
subjects with matched age. It appears that muscle function remains 
lower in ADT patients even several years after the treatment beginning, 
which does not occur with non-ADT patients, since no differences were 
observed in muscle function between non-ADT patients and control 
healthy subjects. Further investigations are required to clarify if strategies, 
such as exercise, can attenuate or even reverse these debilitating side 
effects of androgen deprivation therapy.
All authors declare no potential conflict of interest related to this article
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